Immunotherapy plus chemo before surgery for RAS-mutated colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (pembrolizumab) plus targeted therapy (bevacizumab) and chemotherapy (CapeOX) given before surgery for a specific type of locally advanced colorectal cancer. It is designed for patients whose tumors have a RAS mutation, are BRAF normal, and are microsatellite stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your cancer must have a specific genetic change called a RAS mutation and no BRAF mutation, and it must be 'microsatellite stable' (MSS).
- You must not have received any previous treatment for this cancer.
- You must be in good overall health, with adequate blood counts, kidney function, and liver function.
- You cannot have a history of autoimmune disease (like lupus or rheumatoid arthritis) or another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
This trial tests whether a combination of targeted radiation (SBRT), chemotherapy (CAPEOX), a biologic drug (bevacizumab), and an immunotherapy (PD-1 inhibitor) can help people with a specific type of advanced colorectal cancer that cannot be removed by surgery. It is for patients whose tumors have a RAS gene mutation and are microsatellite stable (MSS).
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests a new drug called LPM6690176 combined with chemotherapy and Avastin (bevacizumab) for people with metastatic colorectal cancer that has a RAS mutation. It may be an option for those who haven't had treatment for their advanced cancer or have already tried one line of therapy.
This trial tests a combination of chemotherapy (CapeOX), a targeted drug (bevacizumab), and an immunotherapy (anti-PD1) given before surgery for colorectal cancer that has come back locally (in the same area). The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a combination of three drugs (doxorubicin liposome, capecitabine, oxaliplatin, and bevacizumab) as a first treatment for advanced colorectal cancer that has a specific SMAD4 gene mutation. The goal is to see if this combination shrinks tumors and is safe for patients who have not had chemotherapy before.
Hear when a new Locally Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.